The role of membrane and vesicular monoamine transporters in the neurotoxic and hypothermic effects of 1-methyl-4-(2′-aminophenyl)-1,2,3,6- tetrahydropyridine (2′-NH2-MPTP)

Molecular Pharmacology

Volumn 66, Issue 3, 2004, Pages 718-727

  Numis, Adam L ^a   Unger, Erica L ^a   Sheridan, Douglas L ^a   Chisnell, Angela C ^a   Andrews, Anne M ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 (2' AMINOPHENYL) 1,2,3,6 TETRAHYDROPYRIDINE; 2 ETHYL 1,2,3,4,6,7 HEXAHYDRO 2 HYDROXY 3 ISOBUTYL 9,10 DIMETHOXY 11BH BENZO[A]QUINOLIZINE; CARRIER PROTEIN; NEUROTOXIN; NORADRENALIN; PROTEIN INHIBITOR; SEROTONIN; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

AMINE TRANSPORT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; BRAIN CORTEX; CELL MEMBRANE TRANSPORT; CONTROLLED STUDY; DOSE RESPONSE; HIPPOCAMPUS; HYPOTHERMIA; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; NORADRENALIN RELEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROTONIN RELEASE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BODY TEMPERATURE; CARRIER PROTEINS; GENE SILENCING; HYPOTHERMIA, INDUCED; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, KNOCKOUT; MPTP POISONING; NERVE TISSUE PROTEINS; NEUROPEPTIDES; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 4944257938     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Ali SF, David SN, Newport GD, Cadet JL, and Slikker W Jr (1994) MPTP-induced oxidative stress and neurotoxicity are age-dependent; evidence from measures of reactive oxygen species and striatal dopamine levels. Synapse 18:27-34.
2. 2-MPTP on serotonergic and noradrenergic nerve terminals. Mol Pharmacol 50:1511-1519.
3. 2-MPTP in Swiss Webster mice: evidence for long term (six month) depletions in cortical and hippocampal 5-HT and NE, differential protection by selective uptake inhibitors or clorgyline and functional changes in central 5-HT neurotransmission. J Pharmacol Exp Ther 267:1432-1439.
4. Andrews AM and Murphy DL (1993b) Fluoxetine and desipramine selectively attenuate 2′-NH2-MPTP-induced depletions in serotonin and norepinephrine. Eur J Pharmacol 250:215-221.
5. 3-MPTP and MPTP. J Neurochem 60:1167-1170.
6. Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, Heils A, Mossner R, Westphal H, and Lesch KP (1998) Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. Mol Pharmacol 53:649-655.
7. Bloem BR, Irwin I, Buruma OJ, Haan J, Roos RA, Tetrud JW, and Langston JW (1990) The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease. J Neurol Sci 97:273-293.
8. Booth RG, Trevor A, Singer TP, and Castagnoli N Jr (1989) Studies on semirigid tricyclic analogues of the nigrostriatal toxin 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine. J Med Chem 32:473-477.
9. Bradbury AJ, Costall B, Domeney AM, Testa B, Jenner PG, Marsden CD, and Naylor RJ (1985) The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety. Neurosci Lett 61:121-126.
10. Frey HH (1975) Hyperthermia induced by amphetamine, p-chloroamphetamine and fenfluramine in the rat. Pharmacology 13:163-176.
11. Freyaldenhoven TE, Ali SF, and Hart RW (1995) MPTP- and MPP(+)-induced effects on body temperature exhibit age- and strain-dependence in mice. Brain Res 688:161-170.
12. Gainetdinov RR, Fumagalli F, Jones SR, and Caron MG (1997) Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 69:1322-1325.
13. Gainetdinov RR, Fumagalli F, Wang YM, Jones SR, Levey AI, Miller GW, and Caron MG (1998) Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J Neurochem 70:1973-1978.
14. German DC, Liang CL, Manaye KF, Lane K, and Sonsalla PK (2000) Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons. Neuroscience 101:1063-1069.
15. Gordon CJ, Watkinson WP, O'Callaghan JP, and Miller DB (1991) Effects of 3,4-methylenedioxymethamphetamine on autonomie thermoregulatory responses of the rat. Pharmacol Biochem Behav 38:339-344.
16. Heikkila RE, Youngster SK, Panek DU, Giovanni A, and Sonsalla PK (1988) Studies with the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and several of its analogs. Toxicology 49:493-501.
17. Heils A, Wichems C, Mossner R, Petri S, Glatz K, Bengel D, Murphy DL, and Lesch KP (1998) Functional characterization of the murine serotonin transporter gene promoter in serotonergic raphe neurons. J Neurochem 70:932-939.
18. Johnson EA, Wu EY, Rollema H, Booth RG, Trevor AJ, and Castagnoli N Jr (1989) 1-methyl-4-phenylpyridinium (MPP+) analogs: in vivo neurotoxicity and inhibition of striatal synaptosomal dopamine uptake. Eur J Pharmacol 166:65-74.
19. Li Q, Wichems C, Heils A, Van De Kar LD, Lesch KP, and Murphy DL (1999) Reduction of 5-hydroxytryptamine (5-HT)(1A)-mediated temperature and neuroendocrine responses and 5-HT(1A) binding sites in 5-HT transporter knockout mice. J Pharmacol Exp Ther 291:999-1007.
20. Lin MT, Wu JJ, and Tsay BL (1983) Serotonergic mechanisms in the hypothalamus mediate thermoregulatory responses in rats. Naunyn Schmiedebergs Arch Pharmacol 322:271-278.
21. Liu Y, Roghani A, and Edwards RH (1992) Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpvridinium. Proc Natl Acad Sci USA 89:9074-9078.
22. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
23. Luellen BA, Miller DB, Chisnell AC, Murphy DL, O'Callaghan JP, and Andrews AM (2003) Neuronal and astroglial responses to the serotonin and norepinephrine neurotoxin: 1-methyl-4-(2′-aminophenyl)-1,2,3,6- tetrahydropyridine. J Pharmacol Exp Ther 307:923-931.
24. Maret G, el Tayar N, Carrupt PA, Testa B, Jenner P, and Baird M (1990) Toxication of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and analogs by mono-amine oxidase. A structure-reactivity relationship study. Biochem Pharmacol 40: 783-792.
25. Markey SP, Johannessen JN, Chiueh CC, Burns RS, and Herkenham MA (1984) Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature (Lond) 311:464-467.
26. Mayer RA, Kindt MV, and Heikkila RE (1986) Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport. J Neurochem 47:1073-1079.
27. Melamed E, Rosenthal J, Globus M, Cohen O, and Uzzan A (1986) Effect of pharmacological manipulations of dopamine metabolism on the dopaminergic neurotoxicity of MPTP in mice, in MPTP: A neurotoxin producing a Parkinsonian syndrome (Markey SP, Castagnoli NP, Trevor AJ, and Kopin IJ eds) pp 473-479, Academic Press, Inc., New York.
28. Miller DB and O'Callaghan JP (1994) Environment-, drug-, and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:752-760.
29. Miller GW, Gainetdinov RR, Levey AI, and Caron MG (1999) Dopamine transporters and neuronal injury. Trends Pharmacol Sci 20:424-429.
30. Montanez S, Owens WA, Gould GG, Murphy DL, and Daws LC (2003) Exaggerated effect of fluvoxamine in heterozygote serotonin transporter knockout mice. J Neurochem 86:210-219.
31. Moy LY, Albers DS, and Sonsalla PK (1998) Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice. Brain Res 790:264-269.
32. Murphy DL, Lesch KP, Aulakh CS, and Pigott TA (1991) Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature and cardiovascular effects in humans. Pharmacol Rev 43:527-552.
33. O'Callaghan JP and Miller DB (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:741-751.
34. Owens MJ, Morgan WN, Plott SJ, and Nemeroff CB (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283:1305-1322.
35. Przedborski S, Kostic V, Jackson-Lewis V, Naini AB, Simonetti S, Fahn S, Carlson E, Epstein CJ, and Cadet JL (1992) Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity. J Neurosci 12:1658-1667.
36. Przedborski S and Vila M (2003) The 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 991:189-198.
37. Ramsay RR, Salach JI, and Singer TP (1986) Uptake of the neurotoxin I-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. Biochem Biophys Res Commun 134:743-748.
38. Reinhard JF Jr, Daniels AJ, and Viveros OH (1988) Potentiation by reserpine and tetrabenazine of brain catecholamine depletions by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) in the mouse; evidence for subcellular sequestration as basis for cellular resistance to the toxicant. Neurosci Lett 90:349-353.
39. Reinhard JF Jr, Diliberto EJ Jr, Viveros OH, and Daniels AJ (1987) Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. Proc Natl Acad Sci USA 84:8160-8164.
40. Saporito MS, Heikkila RE, Youngster SK, Nicklas WJ, and Geller HM (1992) Dopaminergic neurotoxicity of 1-methyl-4-phenylpyridinium analogs in cultured neurons: relationship to the dopamine uptake system and inhibition of mitochondrial respiration. J Pharmacol Exp Ther 260:1400-1409.
41. Schmidt CJ, Black CK, Abbate GM, and Taylor VL (1990) Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors, Brain Res 529:85-90.
42. Speciale SG, Liang CL, Sonsalla PK, Edwards RH, and German DC (1998) The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter. Neuroscience 84:1177-1185.
43. Staal RG, Hogan KA, Liang CL, German DC, and Sonsalla PK (2000) In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4- phenylpyridinium. J Pharmacol Exp Ther 293:329-335.
44. Staal RG and Sonsalla PK (2000) Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. J Pharmacol Exp Ther 293:336-342.
45. Stewart CW, Bowyer JF, and Slikker W Jr (1997) Elevated environmental temperatures can induce hyperthermia during d-fenfluramine exposure and enhance 5-hydroxytryptamine (5-HT) depletion in the brain. J Pharmacol Exp Ther 283: 1144-1150.
46. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, Jackson-Lewis V, Przedborski S, and Uhl GR (1997) VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 94:9938-9943.
47. Uhl GR, Li S, Takahashi N, Itokawa K, Lin Z, Hazama M, and Sora I (2000) The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins. FASEB J 14:2459-2465.
48. Unger EL, Mazzola-Pomietto P, Murphy DL, and Andrews AM (2002) 2′-NH(2)-MPTP [1-methyl-4-(2′-aminophenyl)-1,2,3,6- tetrahydropyridine] depletes serotonin and norepinephrine in rats: a comparison with 2′-CH(3)-MPTP [1-methyl-4-(2′-methylphenyl)-1,2,3,6- tetrahydropyridine]. J Pharmacol Exp Ther 303:527-533.
49. Youngster SK, Sonsalla PK, and Heikkila RE (1987) Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 48:929-934.
50. Youngster SK, Sonsalla PK, Sieber BA, and Heikkila RE (1989) Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs. J Pharmacol Exp Ther 249:820-828.